A5102804418- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Sarcoma Diagnosis and Treatment
- Advanced biosensing and bioanalysis techniques
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cardiac Valve Diseases and Treatments
- Biosimilars and Bioanalytical Methods
- Cardiac Arrhythmias and Treatments
- Cardiac pacing and defibrillation studies
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Cardiac Structural Anomalies and Repair
- Colorectal Cancer Treatments and Studies
- Multiple Myeloma Research and Treatments
- Ocular Oncology and Treatments
- Pulmonary Hypertension Research and Treatments
Research Institute Hospital 12 de Octubre
2022-2024
Hospital Universitario 12 De Octubre
2023-2024
Universidad Autónoma de Madrid
2019-2024
University of Pennsylvania
2024
Hospital Universitario de La Princesa
2017-2024
Ecopetrol (Colombia)
2023
Centro de Investigación Biomédica en Red de Cáncer
2023
Universidad Complutense de Madrid
2023
Array BioPharma (United States)
2022
Tecnológico Nacional de México
2022
IntroductionThe ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study Lung Cancer/Association Molecular Pathology testing guidelines support use immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence situ hybridization (FISH) or molecular test all positive results. We have evaluated novel anti-ROS1 IHC antibody (SP384) large multicenter series to obtain real-world...
Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines metastatic non-squamous non-small-cell lung cancer, and considered mandatory European countries. However, practice, challenges are often faced when carrying out routine biomarker testing, including access to inadequate tissue samples long turnaround times (TATs).To evaluate the real-world EGFR testing practices of pathology laboratories, online survey was set up validated by Pulmonary...
Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and identify biomarkers of long-term chemoimmunotherapy benefit human ES-SCLC.
8532 Background: Neoadjuvant chemotherapy is an accepted treatment approach for resectable NSCLC. Major pathologic response (mPR) defined as ≥ 90% tumor necrosis seen in 20% of patients (pts) receiving neoadjuvant and portends a favorable survival. Combination anti-PD-(L)1 therapy has demonstrated potential synergy metastatic This ongoing phase II study explores the combination atezolizumab + chemotherapy. Methods: Pts with stage IB-IIIA NSCLC receive 4 cycles atezolizumab, nab-paclitaxel,...
Background: Spontaneous coronary artery dissection (SCAD) is an infrequent cause of acute syndrome (ACS); however, its detection carries relevant clinical implications. Cardiac computed tomography (CCT) has been found to be useful for follow-up, but data during the phase are scarce. Thus, our aim was evaluate early diagnostic ability CCT detect SCAD. Methods: We retrospectively analyzed all in-hospital performed in a prospective cohort patients with SCAD from 2012 2016. An independent expert...
To study programmed death ligand 1 (PD-L1) expression, tumour-infiltrating T lymphocytes (TILs) and the molecular context in patients with early-stage squamous cell lung carcinomas (SCCs).The included samples from 40 (discovery cohort) 29 (validation diagnosed SCC. PD-L1 immunohistochemistry (IHC) was performed three commercially available clones (E1L3N, SP263 SP142). CD8+ TILs were scored a digital algorithm. All tumours analysed targeted next-generation sequencing (NGS). Additionally, TP53...
The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated as predictive biomarkers in a "tumor-agnostic" manner. However, the identification of these patients is extremely challenging because overall frequency NTRK fusions below 1%. Academic groups and professional organizations released recommendations on algorithms to detect fusions. European Society for Medical Oncology proposal encourages use next-generation sequencing (NGS) if...
inhibitors with impressive overall response rates are now available for patients NSCLC, yet the identification of
<b><i>Background/Aim:</i></b> Erlotinib and chemotherapy have shown similar efficacy for pretreated non-small cell lung cancer (NSCLC) patients, but none of the large studies selected patients based on histology. We present a retrospective single-center series advanced non-squamous NSCLC treated with erlotinib or pemetrexed as second-line therapy. Our aim was to compare safety data under clinical practice conditions identify subgroups who could benefit more from these...
10075 Background: Uveal melanomas (UM) measuring at least 12mm in base diameter with a class 2 signature as defined by gene expression profiling (DecisionDx-UM) are characterized high metastatic risk, median time to recurrence of 32 months. No therapy has been shown reduce this risk. The growth factor receptor Met is highly expressed UM. We have previously that crizotinib, an inhibitor Met, effective adjuvant preclinical models (Surriga et al, Mol Cancer Ther 2013). therefore conducted phase...
9592 Background: ICI responses in UM are rare (~5% with anti-CTLA4/PD1 monotherapy; 10-12% combination ICI). IMC is a bispecific agent composed of high affinity T cell receptor targeting the gp100 melanoma antigen fused to an anti-CD3 scFv that increases intratumoral CD8+ infiltration and PD1/PDL1 expression, may enhance response post-IMCgp100 ICI. Methods: We previously reported on 19 pts treated phase I dose escalation cohort (IMCgp100-102). performed retrospective analysis clinical...
We try to identify the relationship between immunohistochemical marker expression and lymph node involvement in a cohort of 282 patients followed for 5 years after curative resection NSCLC. In 189 (67 %), nodes were unaffected while 93 (33 %) showed nodal involvement. The 15 molecular markers was determined from each patient by tissue-array immunohistochemistry. Univariate analysis indicated significantly higher E-cadherin, γ-catenin, p27, p53 with those nodes, p16 Rb expressed. E-cadherin...
Malignant fibrous histiocytoma is an aggressive tumor, the most common soft-tissue sarcoma of adult age. It usually located in extremities and retroperitoneum, very rarely there skeletal involvement. Surgery preferred treatment early disease; advanced disease, chemotherapy main therapeutic strategy. We present a 25-year-old female patient diagnosed with vertebral mass T5 severely compromised spinal cord. She underwent surgical decompression pathological findings were consistent malignant...
<p>Supplementary Figures</p>